The European Medicines Agency (EMA) has published the minutes of its Committee for Orphan Medicinal Products (COMP) meeting held on 17-18 March 2026, detailing discussions and decisions on applications for orphan designation, protocol assistance, and other regulatory matters affecting developers of medicines for rare diseases.
Published on 5 May 2026, the minutes cover the COMP's review of several new applications for orphan medicinal product designation, as well as follow-up on previously submitted dossiers. The committee also discussed scientific advice and protocol assistance requests, which are key for companies seeking guidance on development programmes for rare disease treatments.
Document type and status
The document is a formal record of the COMP meeting, providing transparency on the committee's decision-making process. It includes summaries of discussions, outcomes of votes, and recommendations. The minutes are not legally binding but reflect the committee's scientific opinions, which influence EMA's final decisions on orphan designations.
Policy orientations and trade-offs
The minutes reveal the COMP's continued focus on ensuring that orphan designations are granted only to medicines that meet the criteria of significant benefit or satisfactory methods for conditions affecting fewer than 5 in 10,000 people in the EU. The committee balances the need to incentivise innovation for rare diseases with the requirement to maintain high standards of evidence. Some discussions highlighted the challenge of assessing significant benefit when existing treatments are limited, reflecting a trade-off between encouraging early development and ensuring robust data.
Impact on stakeholders
Pharmaceutical companies developing orphan medicines are directly affected, as the COMP's decisions determine eligibility for incentives such as market exclusivity and fee reductions. Patients with rare diseases stand to benefit from accelerated access to new therapies, but may face uncertainty if applications are rejected due to insufficient evidence. National health authorities may see implications for pricing and reimbursement decisions, as orphan designation can influence negotiations. The committee itself maintains its role as a scientific gatekeeper, ensuring that only credible candidates receive designation.
Expected institutional follow-up
The minutes will inform future COMP meetings and EMA's overall orphan medicines policy. Companies whose applications were discussed may receive formal notifications and can request re-examination of negative opinions. The European Commission ultimately grants orphan designations based on COMP recommendations, so the minutes provide early insight into likely regulatory outcomes.